Secondary myelodysplastic syndrome following bone marrow transplantation: report of two cases

Bone Marrow Transplant. 1994 Feb;13(2):145-8.

Abstract

We report two cases of secondary myelodysplastic syndrome (SMDS) which followed successful treatment of a primary malignancy with high-dose chemotherapy supported by reinfusion of autologous stem cells. The SMDS was diagnosed 24 months and 40 months, respectively, following autografting. Both patients lived for 7 months after the diagnosis of SMDS. Our cases support the view that there is an increased risk of SMDS/acute leukemia following autologous marrow transplantation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / administration & dosage
  • Bone Marrow Transplantation / adverse effects*
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Humans
  • Leucovorin / administration & dosage
  • Lymphoma / drug therapy
  • Lymphoma / therapy
  • Male
  • Methotrexate / administration & dosage
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / epidemiology
  • Myelodysplastic Syndromes / etiology*
  • Prednisone / administration & dosage
  • Procarbazine / administration & dosage
  • Rectal Neoplasms / drug therapy
  • Rectal Neoplasms / therapy
  • Risk Factors
  • Seminoma / drug therapy
  • Seminoma / therapy
  • Testicular Neoplasms / drug therapy
  • Testicular Neoplasms / therapy
  • Transplantation, Autologous
  • Vincristine / administration & dosage

Substances

  • Bleomycin
  • Procarbazine
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Leucovorin
  • Prednisone
  • Methotrexate

Supplementary concepts

  • BEACOPP protocol
  • MACOP-B protocol